Your browser is no longer supported. Please, upgrade your browser.
Mirum Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-3.43 Insider Own0.40% Shs Outstand25.13M Perf Week-12.98%
Market Cap485.93M Forward P/E- EPS next Y-3.82 Insider Trans6.68% Shs Float9.89M Perf Month-14.22%
Income-84.00M PEG- EPS next Q-0.72 Inst Own82.50% Short Float6.45% Perf Quarter-31.76%
Sales- P/S- EPS this Y-202.90% Inst Trans15.94% Short Ratio2.94 Perf Half Y-31.81%
Book/sh4.78 P/B3.41 EPS next Y-15.80% ROA-54.50% Target Price- Perf Year-3.50%
Cash/sh4.49 P/C3.63 EPS next 5Y- ROE-61.90% 52W Range9.14 - 27.43 Perf YTD-6.70%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-40.61% Beta-
Dividend %- Quick Ratio7.40 Sales past 5Y- Gross Margin- 52W Low78.23% ATR1.06
Employees67 Current Ratio7.40 Sales Q/Q- Oper. Margin- RSI (14)29.45 Volatility5.79% 5.52%
OptionableNo Debt/Eq0.00 EPS Q/Q-30.50% Profit Margin- Rel Volume1.28 Prev Close17.90
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume217.03K Price16.29
Recom1.40 SMA20-17.25% SMA50-14.72% SMA200-18.16% Volume278,460 Change-8.99%
Aug-07-20Upgrade Raymond James Outperform → Strong Buy $28 → $48
Aug-03-20Initiated H.C. Wainwright Buy $52
Jul-31-20Initiated Piper Sandler Overweight $77
Jun-25-20Initiated Robert W. Baird Outperform $30
Aug-12-19Initiated ROTH Capital Buy $33
Aug-12-19Initiated Raymond James Outperform $28
Aug-12-19Initiated Guggenheim Buy $18
Aug-12-19Initiated Evercore ISI Outperform
Aug-12-19Initiated Citigroup Buy $21
Feb-22-21 09:00AM  
Feb-10-21 05:30PM  
Feb-08-21 10:12AM  
Feb-01-21 09:00AM  
Jan-24-21 09:00AM  
Jan-14-21 09:00AM  
Jan-12-21 09:00AM  
Jan-08-21 06:17PM  
Jan-04-21 08:30AM  
Dec-30-20 02:45AM  
Dec-22-20 08:55AM  
Dec-14-20 09:00PM  
Dec-10-20 10:33PM  
Dec-09-20 09:00AM  
Dec-07-20 09:00AM  
Nov-30-20 08:30AM  
Nov-23-20 09:30AM  
Nov-15-20 06:00PM  
Nov-13-20 08:10AM  
Nov-12-20 09:00AM  
Nov-10-20 07:00PM  
Nov-05-20 08:30AM  
Nov-02-20 08:30AM  
Oct-26-20 08:30AM  
Oct-15-20 08:55AM  
Oct-14-20 10:29AM  
Oct-13-20 04:05PM  
Sep-11-20 04:30PM  
Sep-01-20 09:00AM  
Aug-29-20 08:45AM  
Aug-11-20 05:30PM  
Aug-07-20 04:05PM  
Aug-06-20 04:05PM  
Jul-10-20 05:00PM  
Jun-22-20 02:06PM  
Jun-11-20 04:10PM  
Jun-02-20 08:30AM  
May-29-20 10:05AM  
May-11-20 05:01PM  
May-07-20 04:05PM  
Apr-28-20 04:19PM  
Mar-12-20 04:02PM  
Feb-18-20 04:01PM  
Jan-16-20 09:00AM  
Jan-14-20 09:00AM  
Jan-08-20 08:15PM  
Dec-24-19 10:40AM  
Dec-17-19 07:56AM  
Dec-16-19 08:00AM  
Dec-13-19 04:28PM  
Nov-25-19 08:30AM  
Nov-08-19 08:05AM  
Nov-06-19 04:05PM  
Oct-28-19 04:05PM  
Oct-21-19 10:15AM  
Oct-01-19 04:30PM  
Sep-26-19 08:35AM  
Aug-28-19 04:01PM  
Aug-12-19 09:57AM  
Jul-17-19 06:33PM  
Jul-15-19 10:10AM  
Jul-12-19 12:10PM  
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its lead product candidate is maralixibat, an investigational oral drug that is in Phase 3 clinical trial for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. The company is also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was founded in 2018 and is headquartered in Foster City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Tucker Edwin JonathanChief Medical OfficerDec 28Option Exercise7.704,16732,08636,442Dec 29 04:24 PM
Clements IanChief Financial OfficerDec 23Buy18.612,47045,9757,841Dec 28 04:12 PM
Peetz ChristopherPresident and CEODec 23Buy18.705,00093,480201,570Dec 28 04:06 PM
Tucker Edwin JonathanChief Medical OfficerOct 30Option Exercise7.7025,000192,50031,000Nov 03 05:09 PM
Tucker Edwin JonathanChief Medical OfficerMar 20Buy11.902,50029,7406,000Mar 23 04:47 PM
Tucker Edwin JonathanChief Medical OfficerMar 19Buy9.912,00019,8183,500Mar 23 04:47 PM